ADMA Biologics Inc (ADMA)

Fixed asset turnover

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Revenue (ttm)	US$ in thousands	382,809	330,245	283,177	258,216	234,293	208,108	181,890	154,079	130,481	110,072	93,998	80,944	68,517	58,112	48,069	42,220	40,301	37,248	36,021	29,350
Property, plant and equipment	US$ in thousands	53,694	54,326	55,317	53,835	54,815	56,306	57,371	58,261	56,946	54,951	53,220	50,935	48,394	46,487	44,176	41,593	39,623	37,373	35,061	31,741
Fixed asset turnover		7.13	6.08	5.12	4.80	4.27	3.70	3.17	2.64	2.29	2.00	1.77	1.59	1.42	1.25	1.09	1.02	1.02	1.00	1.03	0.92

September 30, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $382,809K ÷ $53,694K
= 7.13

The fixed asset turnover ratio for ADMA Biologics Inc has shown a generally increasing trend over the past years, indicating improved efficiency in generating sales from its fixed assets. The ratio has consistently increased from 0.92 at the end of 2019 to 7.13 at the end of September 2024. This suggests that the company is utilizing its fixed assets more effectively to generate revenue.

A high fixed asset turnover ratio signifies that the company is generating a higher level of sales relative to its investment in fixed assets. It indicates efficient management of fixed assets and potentially strong operational performance.

Overall, the increasing trend in the fixed asset turnover ratio for ADMA Biologics Inc indicates positive operational efficiency and effective utilization of fixed assets to drive revenue growth over the period under consideration.